For Healthcare Professionals

A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer


About the study

The main purpose of this study is to examine the side effects that participants with metastatic breast cancer experience when taking abemaciclib with or without food.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

Have a diagnosis of HR+, HER2- metastatic breast cancer (mBC).

Have all of the following:

  1. Recurrent, locally advanced, unresectable or mBC with disease progression following anti-estrogen therapy.
  2. Prior treatment with chemotherapy for locally advanced or metastatic disease.
  3. No prior treatment with cyclin-dependent kinases (CDK) 4 and 6 inhibitor.
  4. Have Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1.
  5. Have discontinued all previous treatments for cancer and recovered from the acute effects of therapy.
  6. Have adequate organ function.
  7. Women of child-bearing potential must have a negative pregnancy test.
  8. Are able to swallow tablets/capsules.


Exclusion Criteria:

  1. Are currently receiving treatment in a clinical study involving an investigational product.
  2. Have a serious concomitant systemic disorder.
  3. Have symptomatic central nervous system (CNS) malignancy or metastasis.
  4. Have a symptomatic Human Immunodeficiency Virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.
  5. Have a personal history of syncope of either unexplained or cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest.
  6. Have a history of any other cancer.
  7. Had major surgery within 14 days prior to randomization.
  8. Are breastfeeding.
  9. Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Metastatic Breast Cancer

Age (in years)



Phase 2

Participants needed


Est. Completion Date

Sep 20, 2023

Treatment type



Eli Lilly and Company identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.